Qiming Venture Partners Wins Three Awards at China Venture Capital Research Institute's 2025 Golden Investment Awards
The awards aim to comprehensively recognize investment institutions that have achieved outstanding success in driving industry progress and creating social value over the past year.
Recently, the China Venture Capital Research Institute unveiled the 2025 China Venture Capital Industry Annual Rankings · Golden Investment Awards · Mid-Year List. This year's selection features two major categories — comprehensive and sector-specific — spanning 13 sub-lists that evaluate fundraising, investment, management, exits, and overall influence, offering a comprehensive view of the investment firms that have driven industry progress and created social value over the past year.
Qiming Venture Partners was named to the Top 10 Most Influential Investment Institutions in China, the Top 25 Best Investment Institutions in Artificial Intelligence and Big Data, and the Top 30 Best Investment Institutions in Healthcare.
Qiming Venture Partners
Selected for
Top 10 Most Influential Investment Institutions in China
Top 25 Best Investment Institutions in Artificial Intelligence and Big Data
Top 30 Best Investment Institutions in Healthcare
2025 China Venture Capital Industry Annual Rankings · Golden Investment Awards · Mid-Year List
The rankings are built on data, anchored in performance, and guided by influence — using quantifiable metrics to comprehensively assess participating institutions' strategic positioning, investment capabilities, and market impact.
The China Venture Capital Research Institute pioneered industry awards in 2005, and twenty years later, the Golden Investment Awards — with their quantitative, objective data standards and selection mechanisms — are widely regarded as a barometer and weathervane for China's venture capital industry, carrying significant authority and credibility within the sector.
Source | China Venture Capital Research Institute
Past Highlights
Qiming Honors | Qiming Venture Partners and Its Investors Win Four Awards Including the China Venture Capital Research Institute's 2024 China Venture Capital Industry Annual Golden Investment Awards Qiming Honors | Qiming Venture Partners and Over 10 Portfolio Companies Named to Diyixinsheng's 3rd AI Innovation Pioneers — 2025 China AI Industry Innovation Pioneer List Qiming Honors | Qiming Venture Partners and 8 Portfolio Companies Named to China Innovative Drug Decade of Glory List
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in early- and growth-stage outstanding companies in Technology and Healthcare innovation.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many of Qiming Venture Partners' portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.